Evigrade
DrugsCosmetic ingredientsCalculatorsInteractionsEvigrade SkinEvigrade Meds ↗
ConditionsJournalMethodologyPro for practitioners
ESRU

Ambroxol

AEMPS

Mucolytic agent

ATC code: R05CB06

Updated · Methodology

Indications

C

Productive cough

Adjunct

Used symptomatically for cough with hard-to-clear sputum. Adult dose 30 mg three times daily or extended-release 75 mg once daily. The Cochrane acute-cough review (Smith 2014) showed a modest effect on cough duration and intensity with low certainty. In chronic bronchitis and COPD, long-term ambroxol or N-acetylcysteine modestly reduces exacerbation frequency (Cochrane 2019 mucolytics review in chronic bronchitis and COPD; mucolytics are also noted in ).

Sources

  1. AEMPS: Ficha técnica de Ambroxol (2024)
  2. Cochrane: Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia (2014)
  3. Cochrane: Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease (2019)

ICD-10: R05 · ICD-11: MD12

C

Sore throat

Individual decision

Ambroxol 20 mg lozenges are used for symptomatic pain relief in acute sore throat. Ambroxol has a local anaesthetic action: it blocks sodium channels in sensory nerves (preclinical proof of concept, Schutz 2002). Placebo-controlled RCTs (Fischer 2002; de Mey 2008) showed a modest reduction in pain, but the independent Prescrire 2009 review judged the effect no better than sucking a plain hard candy, and the positive RCTs were manufacturer-funded. The evidence is in genuine equipoise, so the decision to use it is individual. The formulation and mechanism differ from the mucolytic action in productive cough, and this is a separate question. In Spain, Lizipaina Ambroxol 20 mg lozenges are registered (AEMPS). Risks include the rare severe allergic and cutaneous reactions of the ambroxol class ( 2015).

Sources

  1. Arzneimittel-Forschung: Efficacy and tolerability of ambroxol hydrochloride lozenges in sore throat. Randomised, double-blind, placebo-controlled trials regarding the local anaesthetic properties (2002)
  2. Arzneimittel-Forschung: Efficacy and safety of ambroxol lozenges in the treatment of acute uncomplicated sore throat. EBM-based clinical documentation (2008)
  3. Arzneimittel-Forschung: Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat. Clinical proof of concept (2002)
  4. Prescrire International: Ambroxol lozenges: new drug. Sore throat: better to just suck on hard candy (2009)
  5. AEMPS CIMA: Ficha técnica Lizipaina Ambroxol 20 mg pastillas para chupar (AEMPS CIMA, nreg 75763) (2024)

ICD-10: R07.0

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

F

Immune support and respiratory infection care

Not recommended

Ambroxol is a mucolytic that thins sputum. It is prescribed for chronic respiratory diseases with thick sputum – COPD, cystic fibrosis. For acute viral upper respiratory infections in children and adults, ambroxol is widely used for cold prevention and at the first signs of a cold. Ambroxol offers no benefit for immunity or cold prevention: it is a mucolytic, not an immunomodulator. The drug does carry documented risks. The 2015 /PRAC referral on ambroxol and bromhexine confirmed a small risk of severe allergic and cutaneous reactions, including erythema multiforme and Stevens-Johnson syndrome, and of anaphylaxis; the benefit-risk balance for approved uses stayed positive and the product information was updated. If ambroxol was prescribed to a child for a cold without marked thick sputum, consider seeking a second opinion.

Sources

  1. AEMPS: Ficha técnica de Ambroxol (2024)
  2. EMA: Ambroxol and bromhexine-containing medicines – referral (PRAC, CMDh) (2015)
How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

An active metabolite of bromhexine. Reduces bronchial secretion viscosity, stimulates surfactant synthesis by type II alveolocytes, and has mild local anesthetic action in the mouth (used as lozenges for sore throat). Glucuronidation-metabolized. Half-life 7–12 hours. In Spain widely prescribed under Mucosan; evidence for efficacy in acute bronchitis is limited.

Safety

Contraindications

  • Ambroxol hypersensitivity
  • Severe hepatic or renal impairment
  • Age under 2 (most formulations)

Serious adverse effects

  • Severe cutaneous reactions (Stevens–Johnson syndrome, toxic epidermal necrolysis) – EMA issued a 2015 warning
  • Anaphylactic reactions

Common adverse effects

  • Nausea, vomiting
  • Diarrhea
  • Dry mouth
  • Taste alteration (metallic)
  • Skin rash

Pregnancy: can you take Ambroxol?

Avoid in T1 where possible. T2 and T3 use is acceptable when indicated.

Breastfeeding: can you take Ambroxol?

Milk concentrations are low. Compatible with breastfeeding in short courses.

Calculate RIDFull profile on NIH LactMed ↗

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Timing and administration

Take after meals to reduce GI side effects, with plenty of water – adequate hydration aids sputum clearance. Short course, usually 5–7 days in acute bronchitis. Productive cough persisting beyond 3 weeks needs evaluation (X-ray, spirometry) to rule out pneumonia, COPD, and bronchiectasis.

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Ambroxol used for?

Ambroxol is evaluated for the following indications with varying evidence strength: Productive cough (evidence tier C), Sore throat (evidence tier C), Immune support and respiratory infection care (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Ambroxol?

Common side effects of Ambroxol (≥ 1 in 100): Nausea, vomiting, Diarrhea, Dry mouth, Taste alteration (metallic), Skin rash. See the Safety section for uncommon and serious reactions.

Is Ambroxol safe during pregnancy?

Avoid in T1 where possible. T2 and T3 use is acceptable when indicated.

Is Ambroxol compatible with breastfeeding?

Milk concentrations are low. Compatible with breastfeeding in short courses.

Who should not take Ambroxol?

Ambroxol is contraindicated in: Ambroxol hypersensitivity; Severe hepatic or renal impairment; Age under 2 (most formulations). Full list in the Safety section.

Official sources

Direct links to regulator labels. Open in a new tab.

Other drugs in this group

Acetylcysteine, Bromhexine, Carbocisteine, Cloperastine, Dextromethorphan, Guaifenesin, Ivy leaf dry extract (Hedera helix), Paracetamol + Chlorpheniramine + Phenylephrine